Cargando…

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker for predicting relapse in multiple solid cancers. However, the predictive value of ctDNA for disease recurrence remains indefinite in locoregional gastric cancer (GC). Here, we aimed to evaluate the predictive value of ctDNA in this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Shu‐Qiang, Nie, Run‐Cong, Huang, You‐Sheng, Chen, Ying‐Bo, Wang, Si‐Yu, Sun, Xiao‐Wei, Li, Yuan‐Fang, Liu, Ze‐Kun, Chen, Yan‐Xing, Yao, Yi‐Chen, Xu, Yu, Qiu, Hai‐Bo, Liang, Yao, Wang, Wei, Liu, Ze‐Xian, Zhao, Qi, Xu, Rui‐Hua, Zhou, Zhi‐Wei, Wang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693304/ https://www.ncbi.nlm.nih.gov/pubmed/37837629 http://dx.doi.org/10.1002/cac2.12494

Ejemplares similares

Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T(3-4a)N0M0 Gastric Cancer Patients after D2 Gastrectomy
por: Chen, Shi, et al.
Publicado: (2017)

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
por: Yuan, Zhen, et al.
Publicado: (2022)

Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions
por: Lu, Si-Yuan, et al.
Publicado: (2021)

Clinical Impact of Delayed Initiation of Adjuvant Chemotherapy Among Patients With Stage II/III Gastric Cancer: Can We Do Better?
por: Chen, Qi-Yue, et al.
Publicado: (2020)

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer
por: Wang, Yizhuo, et al.
Publicado: (2016)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer
por: Chen, Yuan-Yuan, et al.
Publicado: (2015)

Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis
por: Quan, RenCui, et al.
Publicado: (2016)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases
por: Wang, De-Shen, et al.
Publicado: (2021)

EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
por: Huang, Ching-Wen, et al.
Publicado: (2017)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
por: Gao, Peng, et al.
Publicado: (2018)

Predictive Models of Adjuvant Chemotherapy for Patients with Stage II Colorectal Cancer: A Retrospective Study
por: Wei, Bo, et al.
Publicado: (2017)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis
por: Chen, Wei-Wei, et al.
Publicado: (2022)

Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

The Traditional Chinese Medicine Kangai Injection as an Adjuvant Method in Combination with Chemotherapy for the Treatment of Breast Cancer in Chinese Patients: A Meta-Analysis
por: Xue, Jing-Xian, et al.
Publicado: (2018)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients
por: Zhu, Peng, et al.
Publicado: (2021)

Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis
por: Chao, Xue, et al.
Publicado: (2019)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
por: Chen, Yuanyuan, et al.
Publicado: (2022)

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
por: Sun, Wei, et al.
Publicado: (2023)

Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population
por: Ni, Jia-Yan, et al.
Publicado: (2018)

Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience
por: Liu, Yu, et al.
Publicado: (2020)

Circulating Low Absolute CD4(+) T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
por: Zhang, Ya-Ping, et al.
Publicado: (2019)

The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study
por: Yu, Xing-Fei, et al.
Publicado: (2017)

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
por: Shih, Yu-Hsuan, et al.
Publicado: (2023)

Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
por: Xu, Jian-Bo, et al.
Publicado: (2017)

miR-20b promotes growth of non-small cell lung cancer through a positive feedback loop of the Wnt/β-catenin signaling pathway
por: Ren, Tao, et al.
Publicado: (2019)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Phase I study of adjuvant chemotherapy with nab‐paclitaxel and S‐1 for stage III Lauren's diffuse‐type gastric cancer after D2 resection (NORDICA study)
por: Cui, Yuehong, et al.
Publicado: (2022)

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2016)

Aspartic acid at residue 185 modulates the capacity of HP-PRRSV nsp4 to antagonize IFN-I expression
por: Wei, Ze-yu, et al.
Publicado: (2020)

TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification
por: Lu, Jun, et al.
Publicado: (2020)

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases
por: Liu, Jin-Hwang, et al.
Publicado: (2010)

Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70
por: Lu, Chieh-Sheng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_60t9is035v3gerv942f516n9mo